CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer
Journal of Clinical Investigation · 17.02.2025 · 135 (4)
DOI: 10.1172/jci179393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 24.12.2024. Verfasst von Giulia Fracassi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. Hauptthemen laut MEDLINE: DNA Ligase ATP, Poly(ADP-ribose) Polymerase Inhibitors, CRISPR-Cas Systems, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PARP inhibitors (PARPi) have received regulatory approval for the treatment of several tumors, including prostate cancer (PCa), and demonstrate remarkable results in the treatment of castration-resistant prostate cancer (CRPC) patients characterized by defects in homologous recombination repair (HRR) genes. Preclinical studies showed that DNA repair genes (DRG) other than HRR genes may have therapeutic value in the context of PARPi. To this end, we performed multiple CRISPR/Cas9 screens in PCa cell lines using a custom sgRNA library targeting DRG combined with PARPi treatment. We identified DNA ligase 1 ( LIG1 ), essential meiotic structure-specific endonuclease 1 ( EME1 ), and Fanconi anemia core complex associated protein 24 ( FAAP24 ) losses as PARPi sensitizers and assessed their frequencies from 3% to 6% among CRPC patients. We showed that concomitant inactivation of LIG1 and PARP induced replication stress and DNA double-strand breaks, ultimately leading to apoptosis. This synthetic lethality (SL) is conserved across multiple tumor types (e.g., lung, breast, and colorectal), and its applicability might be extended to LIG1-functional tumors through a pharmacological combinatorial approach. Importantly, the sensitivity of LIG1 -deficient cells to PARPi was confirmed in vivo. Altogether, our results argue for the relevance of determining the status of LIG1 and potentially other non-HRR DRG for CRPC patient stratification and provide evidence to expand their therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
- Institute of Molecular Genetics, National Research Council, Pavia, Italy.
- IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain.
- Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.
Zitieren
APA
Fracassi, G., Lorenzin, F., Orlando, F., Gioia, U., D'Amato, G., Casaramona, A. S., Cantore, T., Prandi, D., Santer, F. R., Klocker, H., d'Adda di Fagagna, F., Mateo, J., & Demichelis, F. (2025). CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. Journal of Clinical Investigation, 135(4). https://doi.org/10.1172/jci179393
Vancouver
Fracassi G, Lorenzin F, Orlando F, Gioia U, D'Amato G, Casaramona AS, et al. CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. Journal of Clinical Investigation. 2025;135(4). doi:10.1172/jci179393
BibTeX
@article{Fracassi2025,
author = {Fracassi, Giulia and Lorenzin, Francesca and Orlando, Francesco and Gioia, Ubaldo and D'Amato, Giacomo and Casaramona, Arnau S and Cantore, Thomas and Prandi, Davide and Santer, Frédéric R and Klocker, Helmut and d'Adda di Fagagna, Fabrizio and Mateo, Joaquin and Demichelis, Francesca},
title = {CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {4},
doi = {10.1172/jci179393}
}
EUVIMED